<DOC>
	<DOCNO>NCT02391480</DOCNO>
	<brief_summary>This Phase 1 , first-in-human , dose escalation study participant advance solid tumor determine pharmacokinetics , maximum tolerate dose recommended Phase 2 dose ABBV-075 different monotherapy dosing schedule . In addition study evaluate safety . tolerability pharmacokinetics ABBV-075 monotherapy combination therapy disease specific expansion cohort .</brief_summary>
	<brief_title>A Study Evaluating Safety Pharmacokinetics ABBV-075 Subjects With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>1 . Participant dose escalation cohort must histological confirmation locally advance metastatic solid tumor either refractory standard care therapy disease standard care therapy exist . 2 . Participants expansion cohort must histological confirmation AML , Multiple Myeloma , breast cancer , NSCLC , prostate cancer , SCLC , NHL either refractory standard care therapy standard care therapy exist . 3 . Participant must Eastern Cooperative Oncology Group ( ECOG ) Performance status : 0 1 ( dose escalation cohort ) 0 2 ( expansion cohort ) 4 . Participants dose escalation cohort must serum albumin â‰¥ 3.2 g/dL screening . 5 . Adequate bone marrow , renal , hepatic function . 6 . QTc interval &lt; 480 millisecond ( msec ) baseline electrocardiogram . 1 . Participant untreated brain meningeal metastasis . 2 . Participant receive anticancer therapy include chemotherapy , immunotherapy , biologic investigational therapy within period 21 day prior Study Day 1 . 3 . Participant active peptic ulcer disease hemorrhagic esophagitis/gastritis . 4 . Symptoms gross hematuria gross hemoptysis . 5 . Exhibits symptomatic persistent , uncontrolled hypertension ( BP &gt; = 140 and/or diastolic pressure &gt; = 90 mm Hg ) . 6 . History long QT syndrome . 7 . Peripheral neuropathy great equal grade 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Bromodomain Inhibitor</keyword>
	<keyword>Cancer</keyword>
</DOC>